Research findings reveal that Tamiflu shortens flu symptoms and reduces flu-related complications.
Oseltamivir (Roche’s Tamiflu) shortens the duration of flu symptoms by approximately a day, in infected patients, according to an analysis published in The Lancet.
The analysis also claims that oseltamivir lowers the risk of lower-respiratory-tract infections that require antibiotics, such as pneumonia, and reduces the need for hospitalization. But the authors of the first complete systematic review[2] of oseltamivir for the Cochrane Collaboration, published in April 2014, dispute these benefits.
